DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450)
South Korea · Delayed Price · Currency is KRW 18,760
+860 (4.80%)
At close: Mar 20, 2026
DongKook Pharmaceutical Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 66,020 | 61,219 | 47,175 | 52,896 | 50,345 |
Depreciation & Amortization | 31,712 | 28,462 | 21,098 | 19,187 | 17,358 |
Loss (Gain) From Sale of Assets | -5,580 | -2,154 | -752.89 | -609.49 | -1,042 |
Asset Writedown & Restructuring Costs | 1,848 | - | - | - | - |
Loss (Gain) From Sale of Investments | 4,723 | -3,284 | 5,814 | 5,434 | -1,376 |
Loss (Gain) on Equity Investments | 3,689 | -2,551 | 896.71 | -1,122 | -1,031 |
Stock-Based Compensation | -115.9 | -39.2 | -162.46 | -297.32 | -24.01 |
Provision & Write-off of Bad Debts | 2,019 | -165.02 | 663.85 | 223.25 | -713.06 |
Other Operating Activities | 8,898 | 19,186 | 2,221 | 5,034 | 3,413 |
Change in Accounts Receivable | -43,703 | -13,751 | -27,785 | -10,664 | 3,656 |
Change in Inventory | -17,181 | -17,310 | -19,223 | -18,019 | -24,747 |
Change in Accounts Payable | 25,029 | 12,561 | 28,954 | 4,606 | -1,349 |
Change in Unearned Revenue | -378.01 | 415.17 | 0.1 | - | - |
Change in Other Net Operating Assets | -8,220 | -6,498 | -17,107 | -15,759 | 163.08 |
Operating Cash Flow | 68,760 | 76,091 | 41,793 | 40,909 | 44,654 |
Operating Cash Flow Growth | -9.63% | 82.07% | 2.16% | -8.39% | -24.45% |
Capital Expenditures | -42,715 | -27,291 | -34,177 | -47,914 | -51,006 |
Sale of Property, Plant & Equipment | 13,423 | 2,998 | 3,579 | 25.35 | 18.27 |
Cash Acquisitions | - | -31,703 | - | - | -13,000 |
Divestitures | - | 2,572 | 2.03 | - | - |
Sale (Purchase) of Intangibles | -3,082 | -3,937 | -5,413 | -4,058 | 1,330 |
Investment in Securities | -34,242 | -5,631 | -21,131 | 31,837 | 16,655 |
Other Investing Activities | 4,927 | 4,747 | 4,757 | 8,507 | 2,220 |
Investing Cash Flow | -61,624 | -64,864 | -52,391 | -12,408 | -43,530 |
Short-Term Debt Issued | 29,041 | 39,571 | 32,358 | 12,670 | 30,687 |
Long-Term Debt Issued | 12,000 | 22,900 | - | 35,000 | 22,500 |
Total Debt Issued | 41,041 | 62,471 | 32,358 | 47,670 | 53,187 |
Short-Term Debt Repaid | -44,741 | -45,999 | -21,084 | -57,836 | -10,854 |
Long-Term Debt Repaid | -3,876 | -27,618 | -3,049 | -22,248 | -3,114 |
Total Debt Repaid | -48,617 | -73,616 | -24,133 | -80,084 | -13,968 |
Net Debt Issued (Repaid) | -7,576 | -11,146 | 8,225 | -32,414 | 39,219 |
Issuance of Common Stock | 18,540 | - | - | - | - |
Dividends Paid | -9,244 | -8,313 | -8,051 | -8,049 | -8,049 |
Other Financing Activities | -2,717 | -2,846 | -2,472 | 672.13 | -1,437 |
Financing Cash Flow | -996.97 | -22,305 | -2,298 | -39,792 | 29,733 |
Foreign Exchange Rate Adjustments | -231.7 | 797.75 | -245.54 | -459.61 | 50.51 |
Net Cash Flow | 5,907 | -10,281 | -13,141 | -11,750 | 30,907 |
Free Cash Flow | 26,046 | 48,800 | 7,616 | -7,005 | -6,352 |
Free Cash Flow Growth | -46.63% | 540.73% | - | - | - |
Free Cash Flow Margin | 2.81% | 6.01% | 1.04% | -1.06% | -1.07% |
Free Cash Flow Per Share | 581.90 | 1090.48 | 170.27 | -156.64 | -142.04 |
Cash Interest Paid | 2,166 | 3,396 | 2,921 | 898.19 | 2,699 |
Cash Income Tax Paid | 23,074 | 11,331 | 16,614 | 11,678 | 19,975 |
Levered Free Cash Flow | 17,053 | 24,190 | -15,328 | -19,169 | -14,977 |
Unlevered Free Cash Flow | 18,352 | 27,001 | -11,661 | -16,469 | -13,175 |
Change in Working Capital | -44,452 | -24,583 | -35,160 | -39,837 | -22,276 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.